Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? Europace. 2017;19:401 6. S10.8-6. Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126:1944 54. S10.8-7. Adamson L, Vohra HA, Haw MP, Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact Cardiovasc Thorac Surg. 2009;9:520 7. S10.8-8. Deal BJ, Scagliotti D, Miller SM, et al. Electrophysiologic drug testing in symptomatic ventricular arrhythmias after repair of tetralogy of Fallot. Am J Cardiol. 1987;59:1380 5. S10.8-9. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Heart Rhythm. 2014;11:e102 65. S10.8-10. Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhyth- mia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol. 2015;8:110 6. S10.8-11. Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmo- nary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779 82. S10.8-12. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replace- ment on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation. 2001;103:2489 94. S10.8-13. Kella DK, Merchant FM, Veledar E, et al. Lesion-specific dif- ferences for implantable cardioverter defibrillator therapies in adults with congenital heart disease. Pacing Clin Electrophysiol. 2014;37:1492 8. S10.8-14. Koyak Z, de Groot JR, Van Gelder IC, et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol. 2012;5:101 10. S10.8-15. Santharam S, Hudsmith L, Thorne S, et al. 